Enanta Pharmaceuticals Inc (ENTA) returns
Enanta Pharmaceuticals returns over 10 years
$1,000 invested in Enanta Pharmaceuticals ten years ago was worth $447.56 at the close on October 30, 2026, with dividends reinvested: an average return of -7.7% a year. The same $1,000 in the S&P 500 (SPY) became $4,166.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | -18.7% | — | $812.59 | -0.9% |
| 3 months | -17.6% | — | $823.85 | +2.1% |
| Year to date | -32.1% | — | $679.14 | +11.7% |
| 1 year | -1.4% | — | $986.19 | +12.4% |
| 3 years | +21.4% | +6.7% | $1,214 | +88.5% |
| 5 years | -87.5% | -34.1% | $124.75 | +76.0% |
| 10 years | -55.2% | -7.7% | $447.56 | +316.6% |
Enanta Pharmaceuticals return by calendar year
| Year | ENTA | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | -32.1% | +11.7% | -43.8% |
| 2025 | +174.3% | +17.7% | +156.5% |
| 2024 | -38.9% | +24.9% | -63.8% |
| 2023 | -79.8% | +26.2% | -106.0% |
| 2022 | -37.8% | -18.2% | -19.6% |
| 2021 | +77.6% | +28.7% | +48.9% |
| 2020 | -31.9% | +18.4% | -50.2% |
| 2019 | -12.8% | +31.2% | -44.0% |
| 2018 | +20.7% | -4.6% | +25.3% |
| 2017 | +75.2% | +21.7% | +53.5% |
| 2016 | +1.5% | +12.0% | -10.5% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also: ENTA financials · ENTA valuation
No forecast, no recommendation. This page describes Enanta Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.